BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, November 27, 2019 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019. The Company granted Mr. Stolz (i) non-qualified stock […]

BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT Study Near-complete Stabilization of TTR Maintained in Participants Throughout Duration of Study […]

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

-Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolio -Delivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2i -Ended quarter with $446.1 million in cash, cash equivalents and marketable securities, excluding Eidos Recent Highlights: BBP-831 – FGFR1-3 inhibitor for achondroplasia: Initiated PROPEL, a prospective observational study in children with […]